QR Pharma licensed several compounds from TorreyPines/Axonyx/NIA-NIH. One of them, bisnorcymserine (BNC), has the potential to enhance cognitive function in advanced AD while at the same time inhibiting APP and amyloid plaque deposition. BNC has been tested in a number of tissue culture cells, brain slices and old rats and found to inhibit butyrylcholinesterase BuChE as well as inhibit APP synthesis and consequently plaque. It has been tested in 3 animal species for tox, pK and pD and an IND is ready to be filed with the FDA.